Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-Breast Cancer
MOH_2020-12-23_009594Phase 2Recruiting
- Sponsor
- Roche
- Start
- Jan 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of giredestrant, inavolisib, ipatasertib, abemaciclib, ribociclib and 5 more in estrogen receptor-positive breast cancer (15 arms), sponsored by Roche. Started Jan 2021; status: recruiting.
02
Drugs
giredestrantinavolisibipatasertibabemaciclibribociclib
03
Conditions
estrogen receptor-positive breast cancer
Beyond the preview
Go deeper on MOH_2020-12-23_009594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-23_009594.